Table 1—

Characteristics of patients and controls and QuantiFERON®–TB Gold in tube results in relation to categorical and continuous variables

TotalDeterminateIndeterminateUnivariateMultivariate
OR (95% CI)p-valuep-value
Categorical variables: controls
 Female62; 60 (50–69)61; 98 (95–100)1; 1.6 (0–7.3)0>0.05>0.05
 Male42; 40 (31–50)42; 100 (98–100)(0–6.7)
Categorical variables: patients
 Male258; 58 (53–62)226; 88 (84–92)26; 10 (6.4–14) 0.6 (0.4–0.9): male <0.05 >0.05
 Female189; 42 (38–47)157; 83 (78–88)32; 17 (12–23)
 Disease group
  Organ transplant233; 52 (48–57)216; 93 (89–96)17; 7.3 (4–11) 0.4 (0.2–0.8) <0.05
   Male157; 67 (61–72)147; 94 (88–97)10; 6.4 (3–11)
   Female76; 33 (27–39)69; 90 (82–96)7; 9.8 (4–18)
  Autoimmune diseases76; 18 (14–22)60; 79 (70–88)16; 21 (12–30) 2.6 (1.4–5.0) <0.05 0.073
   Male22; 29 (20–40)22; 1000; 0
   Female54; 71 (60–80)38; 70 (57–80)16; 30 (19–43)
  Primary immunodeficiency45; 10.1 (7.3–13)41; 91 (83–99)4; 9 (1–18)0.8 (0.3–2.3)>0.05
   Male21; 47 (32–60)20; 96 (76–100)1; 4.2 (0–24)
   Female24; 53 (39–67)21; 87 (68–96)3; 13 (3–31)
  Stem cell transplant42; 9.4 (6.7–12)23; 55 (40–70)19; 45 (30–60) 8.1 (3.0–22) <0.05 <0.05
   Male25; 60 (44–73)11; 44 (27–63)14; 56 (37–73)
   Female17; 40 (27–56)12; 70 (47–87)5; 30 (13–53)
  HIV patients51; 11.4 (8.5–14)49; 96 (91–100)2; 3.9 (0–10) 2.3 (1.5–4.2) <0.05
   Male33; 65 (51–76)32; 97 (83–100)1; 3 (0–17)
   Female18; 35 (24–49)17; 94 (72–100)1; 6 (0–28)
 Medication
  Steroids230; 51 (47–56)195; 85 (80–89)35; 15.2 (11–20)>0.05>0.05
  Cyclosporin147; 33 (29–37)127; 86 (81–92)20; 13.6 (8–19)>0.05>0.05
  Tacrolimus95; 21 (17–25)85; 90 (84–96)10; 10.5 (4–17)>0.05>0.05
  Methotrexate25; 6 (4–8)22; 88 (75–100)3; 12 (0–25)>0.05>0.05
  Mycophenolate173; 39 (34–43)158; 91 (87–96)15; 8.7 (4–13) 0.8 (0.7–1.0) <0.05 >0.05
 Risk factors
  Diabetes31; 7 (5–10)28; 90 (80–100)3; 9.7 (0–20)>0.05>0.05
  Smoking28; 6 (4–9)26; 93 (83–100)2; 7.1 (0–17)>0.05>0.05
  Having had dialysis206; 46 (42–51)190; 92 (89–96)16; 7.8 (4–11)>0.05>0.05
Continuos variables: patients
 Age yrs447; 52.4±13.8389; 52.1±13.758; 53.8±14.2>0.05>0.05
 Erythrocyte count 106·μL−1431; 4.4±0.7374; 4.5±0.757; 3.9±0.7 <0.05 <0.05
 Leukocyte count 1000·μL−1435; 6.9±3.4378; 7±3.457; 6.4±3.4>0.05>0.05
 Lymphocyte count μL305; 1614±836266; 1691±81739; 1085±771 <0.05 <0.05
 CD3 count μL−164; 1114±63756; 1205±6148; 481±421 <0.05 <0.05
 CD4 count μL−178; 462±30068; 483±28910; 313±350>0.05>0.05
 CD8 count μL−174; 585±45264; 656±44610; 134±90 <0.05 <0.05
 Length of dialysis months196; 56±44182; 55.1±4314; 68.5±46>0.05>0.05
 Length of illness months413; 91±90360; 94±8853; 78±102>0.05>0.05
  • Data are presented as n; % (95% confidence interval) or n; mean±sd, unless otherwise stated. Significant differences in univariate and multivariate analysis are shown in bold. QuantiFERON®–TB Gold in tube is manufactured by Cellestis, Carnegie, Australia.